Immunosuppressive strategies to improve outcomes of kidney transplantation.
The introduction of several immunosuppressive agents over the past decade has reduced the rate of acute rejection significantly and has improved short-term renal allograft survival. However, their impact on long-term outcomes remains unclear. Current immunosuppressive strategies are focused on improving long-term graft and patient survival along with maintaining allograft function. The approval of the new immunosuppressive agents: rabbit antithymocyte globulin, basiliximab, daclizumab, tacrolimus, mycophenolate, and sirolimus, also has facilitated the development of steroid- and calcineurin inhibitor-sparing regimens in kidney transplantation. We discuss the impact of various immunosuppressive regimens on the outcome measures of kidney transplantation: acute rejection episodes, allograft survival, and renal function.
Tang
Ignatius Y
IY
Transplantation Medicine, Section of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
Meier-Kriesche
Herwig-Ulf
HU
Kaplan
Bruce
B
D000818:Animals; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007165:Immunosuppression Therapy / Q000592:standards*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
D007166:Immunosuppressive Agents